Radius Health, Inc. (RDUS) is a Waltham, Massachusetts-based development-stage biopharmaceutical company with a focus on the development of new therapeutics for the treatment of osteoporosis and other serious endocrine-mediated diseases.
With no approved products in its portfolio, Radius Health has not generated revenues yet. In this scenario, investor focus remains on updates on pipeline progress. Candidates in the company’s pipeline include the subcutaneous formulation and transdermal patch of abaloparatide, RAD1901 and RAD140. The company is planning to file for approval of abaloparatide-SC in the U.S. and Europe during the second half of 2015.
Although Radius Health beat estimates in two of the last three trailing quarters, the company delivered an average negative earnings surprise of -81.58%. Investors have however, narrowed loss estimates for 2015.
Currently, Radius Health has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Radius Health posted narrower-than-expected loss in the first quarter of 2015. While our consensus called for a loss of 51 cents per share, the company reported a loss of 47 cents.
Revenue: With no approved product in its portfolio, Radius Health has not generated any revenues in the first quarter of 2015.
Key Stats: Radius Health’s efforts towards the development of its pipeline are encouraging. The company is currently gearing up for the submission of marketing applications for the candidate in the U.S. and Europe. Additionally, during the first quarter, Radius Health gained the worldwide rights to RAD1901 by amending its license agreement with Eisai Co. Ltd. (ESALY), which should further help in cultivating the potential therapeutic profile of RAD1901. The company is planning to commence a phase I study on RAD1901 in the EU for metastatic breast cancer in 2015 and a phase IIb study for low-dose RAD1901 for the potential treatment of vasomotor symptoms in the second half of 2015.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment